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Summary: In ten auxiliary partial iver transplant recip- 
ients selective bowel decontamination (SBD) was used 
to reduce infections due to gram-negative microorgan- 
isms and fungi. During SBD no gram-negative infec- 
tions occurred. Candida peritonitis was observed in one 
patient. After discontinuation f SBD serious infections 
of gram-negative origin did occur and three fungal in- 
fections were seen. SBD seems to have a favourable 
effect in reducing infections by gram-negative microor- 
ganisms and fungi. Most striking was the number of 
enterococcal infections that occurred. Five out of ten 
patients developed enterococcal infections which in two 
cases contributed to a fatal outcome. These infections 
occurred after increase of the number of enterococci in 
faeces and concomitant positive cultures of bile, ascites 
or wound drains. This increase could be due to the use 
of SBD. Also, the kind of biliary anastomosis may play 
an important role in the relatively high incidence of 
enterococcal infections. In the postoperative p riod, re- 
currence of hepatitis B infection in the liver graft was 
observed in all patients with cirrhosis due to this virus. 
Problems caused by other viral infections or protozoal 
infections remained limited in these ten patients. 
Zusammenfassung: hfektionen ach partietler auxi- 
liiirer Lebertransplantation. Erfahrungen bei den ersten 
zehn Patienten. Bei Patienten, bei denen eine auxiligre, 
partielle Lebertransplantation durchgefiihrt wurde, 
wurde die selektive Darmdekontamination (SBD) 
eingesetzt, um Infektionen dt~ch gramnegative 
Mikroorganismen und Pilze zu vermindern. Wahrend 
SBD traten keine Infektionen durch gramnegative Bak- 
terien auf. Bei einem Patienten wurde eine Candida- 
Peritonitis beobachtet. Nach Beendigung der SBD kam 
es zu schweren Infektionen durch gramnegative Bakte- 
rien, auf3erdem zu drei Pilzinfektionen. SBD hat often- 
sichtlich einen gtinstigen Einflug im Hinblick auf eine 
Verminderung yon Infektionen durch gramnegative Er- 
reger und Pilze. Bemerkenswert hoch war die Zahl der 
aufgetretenen Enterokokkeninfektionen. Bei ftinf der 
zehn Patienten traten Enterokokkeninfektionen auf, die 
in zwei F~illen den letalen Ausgang mitbestimmten. 
Diesen Infektionen gingen ein Anstieg der Entero- 
kokkenzahlen im Stuhl und zugleich positive Kultnren 
in Galle, Aszites und Wunddrainagen voraus. Es ist 
mrglich, dab die SBD die Zunahme von Enterokokken- 
infektionen begiinstigte. Auch die Art der Gallengangs- 
anastomose kann hierzu wesentlich beigetragen haben. 
Bei allen Patienten, bei denen die Zirrhose durch He- 
patitis.B Virus verursacht war, kam es postoperativ zu 
einem Rezidiv durch dieses Virus im Lebertransplantat. 
Probleme durch andere virale oder Protozoeninfek- 
tionen hMten sich bei diesen zehn Patienten in Grenzen. 
Introduction 
Liver transplantation has long remained in the experimental 
phase but is now an accepted therapy for almost all forms 
of acute and chronic liver failure [1-6]. Infectious compli- 
cations remain a major factor in morbidity and mortality 
among liver t ansplant recipients. The incidence of infec- 
tious complications after liver transplantations has been re- 
ported to be 66 to 88% [7-9]. Gram-negative microorgan- 
isms, fungi and cytomegalovirus (CMV) were the most im- 
portant causative agents. Particularly gram-negative and 
fungal infections resulted in a high mortality (53 to 69%) 
[10, 11]. It has been stated that selective bowel decontami- 
nation (SBD) could result in a lower incidence of gram- 
negative and fungat infections [1, 12]. 
In October 1986 an auxiliary partial liver transplantation 
program was started in our hospital. We did not expect he 
number of patients to be sufficient for a prospective ran- 
domised trial on the effects of SBD. All patients therefore 
received SBD. We report our experiences in the first ten 
patients. 
The relatively high risk of hepatitis B reinfection in 
HBsAg-positive liver transplant patients has often been 
mentioned [13, 14]. The recurrence of hepatitis B virus 
infection of the graft, with or without coinfection with 
hepatitis delta virus, was therefore followed as well. 
Patients and Methods 
Study population, antimicrobia[ therapy, laboratory methods and 
graft function: Between October 1986 and April 1988, 11 auxil- 
iary partial liver transplantations were performed in ten patients. 
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Table 1: Patient characteristics and data on duration and effect of SBD. 
Sex M M M M F F F M M M 
Age* 36 31 40 26 49 53 18 50 32 41 
Etiology of liver failure** HBV ? HBV/HDV PSC/CAH PBC 1AT-def ? HBV HBV/HDV HBV 
Acute/chronic C A C C C C A C C C 
1-year survival + - + + - + - + + - 
Post-operative 
days on ICU 3 21 6 3 17 3 18 2 3 23 
Duration SBD 
Preoperative 4 1 3 6 10 31 2 14 8 35 
Postoperative 13 20 12 11 16 12 16 12 11 24 
SDD achieved 
On day of treatment + - + - + + - + + + 
* age at date of transplantation; 
** HBV = hepatitis B virus; HDV = hepatitis D virus; PSC = primary sclerosing cholangitis; PBC = primary biliary cirrhosis; CAH = hronic active 
hepatitis; 1ATdef = c~lantitrypsin deficiency; ? = diagnosis not possible. 
One patient was retransplanted because of primary non-function 
of the graft. The surgical technique and first results of auxiliary 
partial liver transplantation n our clinic are described in detail 
elsewhere [15]. 
A number of data on patients and on the duration and the effect of 
SBD are listed in Table 1. In nine patients SBD was performed 
with the following orally adminstered regimen four times per day: 
colistin sulfate 200 rag, tobramycin 80 nag and amphotericin B 
500 mg, plus a mouth paste (Orabase R, Squibb, Regensburg, 
FRG) containing the same drugs in concentrations of 2%. Be- 
cause of lack of compliance to tobramycin, this drug was replaced 
by ciprofloxacin, 500 mg twice daily in one patient (no. 10, 
Table 1). The parameter used for the achievement of SBD was 
elimination of gram-negative bacteria and fungi from the rectum 
and from the oropharynx. Patients with acute liver failure were 
started on SBD on admission to our hospital and patients with 
chronic liver disease when they were put on a waiting list for liver 
transplantation (Eurotransplant, Leiden, the Netherlands). SBD 
was discontinued after the last drain was removed. Twenty-four 
hours perioperatively, cefotaxime (4 x I g) and metronidazole (4
x 500 rag) were given intravenously. All patients received anti: 
cytomegalovirus immunoglobulin (Cytotect R, Biotest Pharma 
GmbH, Frankfurt, FRG), 110 U/kg i. v., once before transplanta- 
tion and then on days 3, 7, 14, 30, 60 and 90 after transplantation. 
Both pre- and postoperatively, specimens were examined for bac- 
terial, viral, fungal and protozoal pathogens, The efficacy of SBD 
was monitored by regular surveillaJace of specimens for bacterial 
and fungal pathogens. Bacterial cultures were performed semi- 
quantitatively by using the four-quadrant method for aerobic and 
anaerobic pathogens [16]. The semi-quantitative cultures were 
estimated on a scale from one to four corresponding to the highest 
quadrant with bacterial growth. The preoperative bacteriological 
study consisted of two cultures per week from nose, throat, urine 
and faeces. These cultures were examined particularly for 
presence of gram-negative microorganisms and fungi. After trans- 
plantation, cultures were performed from Mood, bile, wound- 
drain fluid, nose, throat, sputum, urine, faeces and stomach con- 
tents. For the first two weeks after transplantation this was done 
three times per week, subsequently once a week. Also, in case of 
signs of a bacterial or fungal infection, cultures from the infection 
site and blood cultures were performed. 
Serum for virological study was obtained shortly before trans- 
plantation and in weeks 1, 2, 5, 8 and 11 after transplantation, and 
subsequently at every outpatient check. Before transplantation, 
the serum of patients was examined for antibodies against hep- 
atitis A, B and delta, herpes implex virus, varicella-zoster virus, 
cytomegalovirus und human immunodeficiency virus. After 
transplantation, detection of antibodies (IgM and IgG) to cyto- 
megalovirus was done routinely. At the same times throat swabs 
and urine and blood samples were taken for rapid virus culture 
technique for demonstration f cytomegalovirus [17]. Antibody 
detection and cultures for the other viruses mentioned above were 
carried out only if indicated clinically. To monitor toxoplasma 
infections serum specimens were obtained from the recipients 
before surgery and at the times as mentioned for virus serology 
after transplantation. Serum from liver donors was acquired when 
available. Detection of antitoxoplasma IgG and IgM was under- 
taken with indirect ELISAs [18]. Portions of all sera were stored 
and run in parallel at a later date. 
Definitions of infections: Infections were recorded according to 
the CDC definitions for nosocomiaI infections [19]. Primar2¢ cyto- 
megalovirus infections were defined either by isolation of virus or 
by serocoversion i  a patient who was eronegative b fore trans- 
plantation. Toxoplasma infections were defined either by a sere- 
conversion or by a fourfold increase in antibody titer. 
Immunosuppression: Immunosuppressive treatment was adminis- 
tered by means of intravenous infusion of prednisolone (25 
mg/day), antilymphocyte globulin (ALG, Institut Mdrieux, Lyon, 
France, 425 lymphocytotoxic units&g/day) and azathioprine 
(1 mg/kg/day). Prednisolone was tapered off in 14 days to a main- 
tenance dose of 10-15 mg/kg orally. Cyclosporin A was given 
i. v. on the sixth postoperative day at a dose of 3 mg/kg/day and 
subsequently atdoses aiming at a serum level of 200 ng/l (poly- 
clonal radioimmunoassay kit of Sandoz, Basel). After removal of 
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Table 2: Bacterial infections and culture results during SBD (<_ 20 days after transplantation) and post-recolonization period 
(> 20 days after transplantation). 
1 None Sepsis Escherichia coli 
Urinary tract Klebsiella/Escherichia coli 
2 Peritonitis Staphylococcus epidermidis / 
Enterococcus 
3 None Urinary tract Klebsiella 
4 None Stomatitis Candida albicans 
Cholangitis ND* 






10 Wound Enterococcus 
Peritonitis Candida albicans 
Peritonitis Enterococcus 
Wound Staphylococcus aureus 
Stomatitis Candida albicans 
Cholangitis Escherichia coli 
Liver abscess Candida albicans 
Liver abscess Pseudomonas 
Wound Enterococcus/Pseudomonas 
Cholangitis Enterococcus~seudomonas 
* ND = culture not done. 
the biliary-drainage catheter in he bowel lumen on the tenth 
postoperative day oral administration of cyclosporin was started. 
This was adjusted to trough serum levels between 100 and 200 
rig/1. ALG and azathioprine were discontinued aft r the seventh 
postoperative day. 
Transplant function: Transplant function was tbllowed by means 
of determination of coagulation factors, liver enzymes, serum 
bilirubin and serum albumin. Also, on preset days Doppler ultra- 
sonography, scintigrapy with technetium-99m-labeled diethyli- 
midodiacetic acid and liver puncture were carried out. 
Results 
Four out of ten patients died in the early postoperative 
period (up to one month after transplantation [20]) with an 
inadequate or non-functioning graft. This applies to two 
patients with acute liver failure and two patients with 
chronic liver disease. In the other six patients, the graft 
function was good. SBD was started in the ten patients one 
to 35 days before transplantation (Tab}o 1). In three pa- 
tients, cultures howed that SBD had not been achieved on 
the day of transplantation. These were patients 2, 4 and 7 
who on the date of transplantation had received the SBD 
regimen for one, six and two days, respectively. SBD was 
achieved later in patients 4 and 7, on the third and sixth day, 
respectively, after transplantation. In patient 2, aerobic 
gram-negative bacteria were eliminated on the fourth post- 
operative day. Yeasts could be cultured from this patient's 
oropharynx throughout the SBD period. In three of the four 
patients who died, SBD was discontinued one to two days 
before death because of the bad prognosis. 
For the determination f the nature and course of infections, 
in this study the postoperative period was divided into a 
period in which effects of SBD might affect the nature of 
the infections, and the period after recolonization of the 
digestive tract. In the six patients with an uncomplicated 
immediate postoperative course, the duration of SBD was 
11 to 13 days, and the bacteriologic cultures howed that 
the duration of recolonization after termination of SBD was 
at most seven days. In view of these findings, the second of 
our two periods for determination of infections was 
reckoned to begin on day 21 after transplantation. The dura- 
tion of follow-up varied from eight to 26 months (end date 
31 December 1988). 
Table 2 lists the findings concerning the nature and the 
causative organisms of the bacterial infections observed. 
No gram-negative infections were observed in the first 20 
days after transplantation. Patient 10 developed a Candida 
peritonitis. This patient died in spite of parenteral treatment 
with amphotericin B. During the post-recolonization period 
(> 20 days after transplantation), serious infections of 
gram-negative origin occurred. In one patient (no. 1), E. 
coli bacteremia developed without a clear source. The uri- 
nary tract infection by E. coli in this patient was only ob- 
served 19 days after the sepsis. In another patient (no. 9) E. 
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coli sepsis developed immediately after a routinely per- 
formed liver puncture three months after transplantation. 
Cholangitis must have been the source of this infection. The 
patient went into septic shock with severe renal failure 
necessitating a protracted stay in an ICU. During this stay, 
the patient was found to have developed a liver abscess due 
to Candida albicans. This abscess was drained and treated 
with amphotericin B intravenously. Subsequently, the ab- 
scess cavity became infected with Pseudomonas. Two 
months later, the patient once more developed cholangitis. 
From the bile, enterococci and again Pseudomonas were 
cultured. The cholangitis was found to be due to an obstruc- 
tion of the choledochus that was corrected surgically. 
Thereafter the patient remained free of symptoms. Two 
patients (no. 1 and 3) developed a urinary tract infection 
with KlebsieUa plus E. coli, and Klebsiella, respectively. 
In the postrecolonization phase the buccal mucosa in two 
patients (no. 4 and 8) showed a white coating. Cultures 
yielded C. albicans. Both patients were given antifungal 
treatment orally. It was observed that in five out of ten 
patients enterococci were cultured. During the first 20 days 
after transplantation, this microorganism was cultured from 
the bile drain in three cases (patients 3, 5 and 10). Clinical 
sepsis was diagnosed in patients 2 and 5. Both had peri- 
tonitis caused by enterococci and S. epidermidis. In one of 
these patients (no. 2), blood cultures positive for both or- 
ganisms were obtained. In the other patient, the blood cul- 
tures remained negative. Both patients died of septic shock. 
During the post-recolonization phase, also, two patients de- 
veloped enterococcal infections. One, a woman (no. 6) with 
an initially uncomplicated course, was readmitted 40 days 
after transplantation with high fever and abdominal pain. 
These symptoms proved to be due to peritonitis and sepsis 
caused by enterococci. In the other patient (no. 9), entero- 
cocci were cultured from an abdominal wound and from 
blood, and two months afterwards enterococci were cul- 
tured from bile. This time the patient had cholangitis due to 
an obstruction of the common bile duct. 
Apart from a severe infection of the transplant with HBV, 
which occurred in all evaluable HBsAg-positive patients, 
problems due to viral infections remained limited in these 
ten patients. The data of the patients with regard to hepatitis 
B are summarized in Table 3. In the four evaluable patients 
(patient 10 died in the immediate post-operative p riod), 
the serological findings suggest a pronounced increase of 
the activity of hepatitis B infection. HBe-antigen appeared 
and anti-e antibodies disappeared, and the HBV-DNA in 
the serum either appeared or rose markedly. Pathological 
examination of liver biopsies (results not included here) 
confirmed the existence of an infection of the liver aUo- 
grafts in all four patients. Antibodies against hepatitis delta 
virus were present in two of the five HBsAg-positive pa- 
tients. 
As mentioned, all patients received passi~,e immunization 
by means of anti-CMV immunoglobulin (CytotectR). One 
patient (no. 3) developed a primary CMV infection with 
high IgM-CMV titres and persistently positive virus cul- 
tures from urine, throat and blood in the period from two to 
14 months after transplantation. There were no clinical 
symptoms during this infection. 
Before transplantation, eight of the ten patients showed 
serological evidence of (latent) toxoplasma infection with 
antitoxoplasma IgG or IgM or both. Three recipients (one 
seronegative for Toxoplasma gondii infection, patient 4 re- 
ceived the graft from a donor seropositive for T. gondii. 
The serological status for toxoplasma infection was not 
known in six donors. Immediately after transplantation 
antitoxoplasma IgG, with an indirect ELISA IgG titer of up 
to 1 : 80, was found in sera of three recipients that was not 
detected anymore after seven weeks and apparently was 
passively acquired by blood transfusion. Two seropositive 
recipients howed a significant fourfold rise in anti-toxo- 
plasma IgG titer followed by a conversion in IgM titer 
(from < 1 : 20 to 1 : 40). The peak in IgG titers were 
reached five (1 : 1280) and 65 weeks (1 : 640) after surgery, 
in patient 3 and 1, respectively. In the first patient this 
occurred after an episode of intensified immunosuppression 
and in the second case concomitantly with a reinfection of 
hepatitis B virus of the graft. 
Discussion 
In Rotterdam, 11 auxiliary partial liver transplantations 
were performed in ten patients between October 1986 and 
April 1988. All patients received selective bowel decon- 
tamination (SBD) to prevent infections by gram-negative 
microorganisms and fungi. According to throat and faecal 
Table 3: Serological findings in hepatitis B positive patients undergoing auxiliary partial liver transplantation. 
1 + + - + - + + - - +*  - 
3 + + - + - + + - - +*  + 
8 + + - + + + - - + +* - 
9 + + - + - - + - - +* + 
10 + NE - + - NE  + NE - NE  - 
Resu l ts  a f te r  t ransp lantat ion  are  determined  three  months  a f ter  date  o f  operat ion .  
NE  = not  eva luab le  ( surv iva l  less  than  three  months) .  
* inc reased  up  to max imal  va lue  o fHBV-DNA > 26700 pg /ml .  
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cultures gram-negative organisms were eliminated in all 
patients before or shortly after transplantation. Only one 
patient failed to clear yeasts from his oropharynx. 
No gram-negative infections developed in the first 20 post- 
operative days. Candida peritonitis was observed in one 
patient. After discontinuation of SBD, serious gram-nega- 
tive infections and three fungal infections were seen. Ac- 
cordingly, we conclude that in this group of patients SBD 
had a favourable ffect in that it reduced infections by 
gram-negative microorganisms and fungi. 
Most striking was the number of enterococcal infections 
that occurred in five out of ten patients. Examination of all 
surveillance cultures of patients who contracted an entero- 
coccal infection showed in most cases an increase of en- 
terococci in the faeces almost immediately after transplant- 
ation. A few days later, enterococci were then cultured 
from the wound area, bile drain or ascites fluid, and peri- 
tonitis and/or sepsis ometimes ensued. In at least wo cases 
enterococci ontributed to a fatal outcome. The frequent 
presence of enterococci ultured from specimens from liver 
transplant recipients an the development of enterococcal 
infections were mentioned only recently by Warren [21]. 
These patients all received systemic antibiotic prophylaxis 
for the prevention of gram-negative infections. The effect 
of SBD and of various other antibiotics on the composition 
of the faecal flora has often been described [22-26]. With 
SBD the aerobic gram-negative microorganisms can be 
eliminated from the bowel but enterococci remain at the 
same level or even rise in number. Although enterococci 
are regularly observed in the faeces of neutropenic patients 
protected by SBD, these bacteria rarely give rise to infec- 
tious manifestations in these patients. Our observations 
may point to the fact that liver transplant recipients who are 
protected by SBD remain at risk of acquiring infections 
caused by gram-positive microorganisms, especially en- 
terococci. It must be stressed that metronidazole and cefo- 
taxime, used in this study as perioperative prophylaxis, do 
not disturb the intestinal anaerobic flora and thus do not 
interfere with the SBD [16]. 
The reconstruction f the biliary tract during the operation 
can be performed either by choledochocholedochostomy 
(end to end anastomosis ofthe donor's and recipient's com- 
mon bile ducts) or by choledochojejunostomy (anastomosis 
of the common bile duct of the graft to the jejeunum) [51. In 
our group choledochojejunostomy wasperformed in all pa- 
tients. The possibility should be considered that this method 
constitutes a greater hazard with respect to infectious com- 
plications as mentioned by Kusne et al [9]. 
In four evaluable patients with cirrhosis due to hepatitis B 
virus (HBV), infection of the graft with HBV occurred as 
suggested by serological and pathological findings. Re- 
activation of chronic hepatitis B may be seen in transplant 
patients given immunosuppression [27-29]. In liver trans- 
plant patients this infection is of special importance as a 
potential cause of graft failure [13, 14]. 
Cytomegalovirus and toxoplasmosis were reported to cause 
severe infections in liver transplant patients [30-33]. In our 
patients, however, no clinical problems from these organ- 
isms were seen. 
In conclusion, there seems to be a favourable ffect of SBD 
in that it may reduce infections of gram-negative or fungal 
origin. In our patients enterococcal infections took place in 
half of the patients. The use of SBD and the kind of biliary 
tract anastomosis probably play an important role. The 
findings in our patients with regard to the enterococcal in- 
fections give r ason to react alertly with antimicrobial ther- 
apy on the appearance ofenterococci in ascites or bile cul- 
tures in liver transplant recipients. 
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